hydroxychloroquine (Z0188) — Competitive Intelligence Brief

hydroxychloroquine (Z0188) (hydroxychloroquine (Z0188)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial. Area: Infectious Diseases.

phase 3 Antimalarial Plasmodium Infectious Diseases Small molecule

Target snapshot

hydroxychloroquine (Z0188) (hydroxychloroquine (Z0188)) — Sanofi. Hydroxychloroquine is an antimalarial drug that works by inhibiting the growth and replication of Plasmodium parasites in the red blood cells.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
hydroxychloroquine (Z0188) TARGET	hydroxychloroquine (Z0188)	Sanofi	phase 3	Antimalarial	Plasmodium
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
arthemether + lumefantrine	arthemether + lumefantrine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum heme detoxification pathway; artemisinin-derived endoperoxide bridge
PQ supervised	PQ supervised	Menzies School of Health Research	marketed	8-aminoquinoline antimalarial	Plasmodium hypnozoites (mechanism not fully elucidated at molecular level)
artesunate (AS)	artesunate (AS)	London School of Hygiene and Tropical Medicine	marketed	Artemisinin derivative	Plasmodium heme and iron-dependent mechanisms
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial class)

1. London School of Hygiene and Tropical Medicine · 6 drugs in this class
2. Sanofi · 3 drugs in this class
3. Epicentre · 2 drugs in this class
4. University of Oxford · 2 drugs in this class
5. · 2 drugs in this class
6. Frantz Viral Therapeutics, LLC · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Institut de Recherche pour le Developpement · 1 drug in this class
9. Centre de Recherche Médicale de Lambaréné · 1 drug in this class
10. GlaxoSmithKline · 1 drug in this class